Twist Bioscience Corporation (NASDAQ:TWST) Shares Sold by Victory Capital Management Inc.

Victory Capital Management Inc. trimmed its stake in shares of Twist Bioscience Corporation (NASDAQ:TWST) by 1.8% in the 1st quarter, HoldingsChannel reports. The firm owned 365,429 shares of the company’s stock after selling 6,862 shares during the period. Victory Capital Management Inc.’s holdings in Twist Bioscience were worth $14,347,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of TWST. Versant Capital Management Inc boosted its stake in shares of Twist Bioscience by 547.2% during the first quarter. Versant Capital Management Inc now owns 686 shares of the company’s stock worth $27,000 after buying an additional 580 shares during the period. GAMMA Investing LLC lifted its position in shares of Twist Bioscience by 68.1% during the 1st quarter. GAMMA Investing LLC now owns 748 shares of the company’s stock valued at $29,000 after acquiring an additional 303 shares during the period. Banque Transatlantique SA acquired a new stake in shares of Twist Bioscience during the 4th quarter valued at approximately $43,000. GF Fund Management CO. LTD. acquired a new stake in shares of Twist Bioscience during the 4th quarter valued at approximately $58,000. Finally, Pallas Capital Advisors LLC acquired a new stake in shares of Twist Bioscience during the 1st quarter valued at approximately $201,000.

Twist Bioscience Trading Up 0.6%

Twist Bioscience stock opened at $36.03 on Thursday. The company has a 50 day moving average price of $33.93 and a 200 day moving average price of $39.28. Twist Bioscience Corporation has a 52 week low of $27.12 and a 52 week high of $60.90. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.24 and a current ratio of 4.51. The firm has a market capitalization of $2.16 billion, a price-to-earnings ratio of -11.09 and a beta of 2.41.

Twist Bioscience (NASDAQ:TWST) last released its earnings results on Monday, May 5th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.10). Twist Bioscience had a negative return on equity of 33.48% and a negative net margin of 54.98%. The company had revenue of $92.79 million during the quarter, compared to analysts’ expectations of $92.00 million. Research analysts forecast that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Insider Activity at Twist Bioscience

In other news, CFO Adam Laponis sold 2,449 shares of the business’s stock in a transaction dated Wednesday, July 9th. The shares were sold at an average price of $38.15, for a total transaction of $93,429.35. Following the transaction, the chief financial officer owned 103,569 shares in the company, valued at approximately $3,951,157.35. The trade was a 2.31% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Paula Green sold 1,101 shares of the company’s stock in a transaction dated Monday, May 5th. The shares were sold at an average price of $37.65, for a total transaction of $41,452.65. Following the completion of the sale, the senior vice president directly owned 129,380 shares in the company, valued at approximately $4,871,157. The trade was a 0.84% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 22,903 shares of company stock worth $794,706. Insiders own 3.01% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently weighed in on TWST shares. Robert W. Baird cut their target price on Twist Bioscience from $54.00 to $44.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 6th. Guggenheim reaffirmed a “buy” rating and set a $50.00 price target on shares of Twist Bioscience in a research report on Tuesday, May 6th. JPMorgan Chase & Co. decreased their price target on shares of Twist Bioscience from $40.00 to $33.00 and set an “underweight” rating for the company in a research report on Tuesday, May 6th. The Goldman Sachs Group decreased their price target on shares of Twist Bioscience from $55.00 to $48.00 and set a “buy” rating for the company in a research report on Tuesday, May 6th. Finally, Barclays decreased their price target on shares of Twist Bioscience from $58.00 to $45.00 and set an “overweight” rating for the company in a research report on Thursday, April 10th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $50.40.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.